Patents by Inventor Catherine STEHMAN-BREEN

Catherine STEHMAN-BREEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating lower back pain
    Patent number: 11491222
    Abstract: A method of treating a patient suffering from low back by administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: November 8, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Catherine Stehman-Breen, John Davis
  • Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
    Patent number: 11472870
    Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: October 18, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gregory Geba, Paula Dakin, Stephen DiMartino, Haitao Gao, Sr., Jennifer Maloney, John Davis, Catherine Stehman Breen
  • Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
    Publication number: 20220041708
    Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gregory GEBA, Paula DAKIN, Stephen DIMARTINO, Haitao GAO, Jennifer MALONEY, John DAVIS, Catherine Stehman BREEN
  • METHOD OF AVERTING OPIOID ADDICTION
    Publication number: 20210060159
    Abstract: A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.
    Type: Application
    Filed: July 2, 2020
    Publication date: March 4, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Catherine STEHMAN-BREEN, John DAVIS
  • Method of averting opioid addiction
    Patent number: 10736961
    Abstract: A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 11, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Catherine Stehman-Breen, John Davis
  • PHARMACEUTICAL COMPOSITION FOR SAFE AND EFFECTIVE TREATMENT OF KNEE AND/OR HIP PAIN
    Publication number: 20200048337
    Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 13, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gregory Geba, Paula Dakin, Stephen DiMartino, Haltao Gao, Sr., Jennifer Maloney, John DAVIS, Catherine Stehman BREEN
  • METHOD OF AVERTING OPIOID ADDICTION
    Publication number: 20180147280
    Abstract: A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (LBP). The method comprises: diagnosing the patient as suffering from low back; administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and avoiding administration of an opioid to the patient, and thereby relieving pain, and averting opioid addiction in a patient.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 31, 2018
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Catherine STEHMAN-BREEN, John DAVIS